Top of mind for the fillfinish market on the CDMO/CMO side is Novo Holdings $16.5-billion acquisition of the CDMO, Catalent, a deal which closed last December (December 2024) and Novo Holdings subsequent sale of three fillfinish sites to Novo Nordisk for $11 billion to support Novo Nordisks blockbuster GLP-1 agonists, Ozempic/Wegovy (semaglutide), respectively for treating Type 2 diabetes and obesity
Effects of carob (Ceratonia siliqua) on sperm quality, testicular structure, testosterone level and oxidative stress in busulfan-induced infertile mice
The cause of many weight issues in todays modern society is insulin dysfunction
Quality concerns with compounded oral semaglutide drops Not all compounded semaglutide drops are created equal
6 Alternative Topical Preparations Compounding topical pain preparations for arthritis patients may help reduce potential opioid addiction and possible exacerbation of OA progression from prolonged use of NSAIDs
Reconstituted Retatrutide: How Long It Lasts and Safe Storage How long reconstituted retatrutide lasts is a critical question for anyone handling this investigational peptide within an authorised clinical setting
